Evidence map›Paper›PMID 34308321›Full record

ArticleEClinicalMedicine2021

Implementation of a pooled surveillance testing program for asymptomatic SARS-CoV-2 infections in K-12 schools and universities.

Rachelle P Mendoza, Chongfeng Bi, Hui-Ting Cheng, Elmer Gabutan, Guillerre Jan Pagaspas, Nadia Khan, Helen Hoxie, Stephen Hanna, Kelly Holmes, Nicholas Gao and 33 more

Open access · goldAbstract read
In one paragraph

Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Scalable solutions for global health: the SalivaDirect model.Frontiers in cellular and infection microbiology · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Validation of RT-qPCR test for SARS-CoV-2 in saliva specimens.Journal of infection and public health · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

43 authors at 4 institutions in 1 country.

Rachelle P MendozaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Chongfeng BiMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Hui-Ting ChengMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Elmer GabutanMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Guillerre Jan PagaspasMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Nadia KhanMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Helen HoxieMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Stephen HannaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Kelly HolmesMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Nicholas GaoMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Raychel LewisMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Huaien WangMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Daniel NeumannMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Angela ChanMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Meril TakizawaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
James LoweMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Xiao ChenMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Brianna KellyMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Aneeza AsifMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Keena BarnesMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Nusrat KhanMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Brandon MayMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Tasnim ChowdhuryMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Gabriella PolloniniMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Nourelhoda GoudaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Chante GuyMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Candice GordonMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Nana AyoluwaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Elvin ColonMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Noah Miller-MedzonMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Shanique JonesMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Rauful HossainMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Arabia DodsonMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Meimei WengMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Miranda McGaskeyMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Ana VasilevaMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Andrew E LincolnMedStar Sports Medicine Research Center, MedStar Health Research Institute, 2900 S Hanover St., Baltimore, MD 21225, USA.
Robby SikkaMinnesota Timberwolves, 600 Hennepin Ave, Minneapolis, MN 55403, USA.
Anne L WyllieDepartment of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College St, New Haven, CT 06510, USA.
Ethan M BerkeOptumLabs, UnitedHealth Group, 12700 Whitewater Dr, Minnetonka, MN 55343 USA.
Jenny LibienDepartment of Pathology, SUNY Downstate Health Sciences University, 450 Clarkson Ave., Brooklyn, NY 11226, USA.
Matthew PincusMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
Prem K PremsrirutMirimus Inc, 760 Parkside Ave. Suite 206, Brooklyn, NY 11226, USA.
SUNY Downstate Health Sciences University · USGeorgetown University · USOptum (United States) · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

backgroundThe negative impact of continued school closures during the height of the COVID-19 pandemic warrants the establishment of cost-effective strategies for surveillance and screening to safely reopen and monitor for potential in-school transmission. Here, we present a novel approach to increase the availability of repetitive and routine COVID-19 testing that may ultimately reduce the overall viral burden in the community.

methodsWe implemented a testing program using the SalivaClear࣪ pooled surveillance method that included students, faculty and staff from K-12 schools (student age range 5-18 years) and universities (student age range >18 years) across the country (Mirimus Clinical Labs, Brooklyn, NY). The data analysis was performed using descriptive statistics, kappa agreement, and outlier detection analysis.

findingsFrom August 27, 2020 until January 13, 2021, 253,406 saliva specimens were self-collected from students, faculty and staff from 93 K-12 schools and 18 universities. Pool sizes of up to 24 samples were tested over a 20-week period. Pooled testing did not significantly alter the sensitivity of the molecular assay in terms of both qualitative (100% detection rate on both pooled and individual samples) and quantitative (comparable cycle threshold (Ct) values between pooled and individual samples) measures. The detection of SARS-CoV-2 in saliva was comparable to the nasopharyngeal swab. Pooling samples substantially reduced the costs associated with PCR testing and allowed schools to rapidly assess transmission and adjust prevention protocols as necessary. In one instance, in-school transmission of the virus was determined within the main office and led to review and revision of heating, ventilating and air-conditioning systems.

interpretationBy establishing low-cost, weekly testing of students and faculty, pooled saliva analysis for the presence of SARS-CoV-2 enabled schools to determine whether transmission had occurred, make data-driven decisions, and adjust safety protocols. We provide strong evidence that pooled testing may be a fundamental component to the reopening of schools by minimizing the risk of in-school transmission among students and faculty.

fundingSkoll Foundation generously provided funding to Mobilizing Foundation and Mirimus for these studies.

Indexed as

Asymptomatic infectionsK-12 schoolsPooled surveillance testingSARS-CoV-2

Identifiers

PMID34308321
PMCPMC8286123
OpenAlexW3185861682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.